New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is in hot pursuit.
The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback